Target intelligence / Profile preview

RBM26 antisense RNA 1 (RBM26-AS1)

Target
RBM26-AS1
Molecular classification
Long non-coding RNA (lncRNA), Antisense RNA
01

Overview

RBM26 antisense RNA 1 (RBM26-AS1) is a long non-coding RNA located on chromosome 13q31.1, transcribed antisense to the protein-coding RBM26 gene[4]. While previously annotated as non-protein coding, recent studies demonstrate that RBM26-AS1 may encode short micropeptides that promote colon cancer cell growth by enhancing nucleocytoplasmic transport and protein processing in the endoplasmic reticulum[2]. There is currently no known specific biological function assigned to the lncRNA itself in normal physiology, though it likely regulates gene expression of RBM26 and possibly other related genes, consistent with mechanisms observed for antisense RNAs[3][7]. As of now, RBM26-AS1 is not considered a classical therapeutic target, and no clinical drugs interact with it directly[2][4][7].

Other names
RBM26 antisense RNA 1 (non-protein coding)RBM26-AS1
02

Mechanism of action

For antisense oligonucleotides (ASOs) targeting antisense RNAs: RNA degradation via RNase H, modulation of RNA stability, interference with mRNA translation. The RBM26-AS1-encoded micropeptide may enhance nucleocytoplasmic transport and ER protein processing.

03

Biological functions

Regulation of gene expression, especially in cis by modulating the expression of its sense counterpart RBM26Potential encoding of micropeptides with regulatory roles in cell proliferation and protein processing, as recently discovered
04

Disease associations

Cancer (specifically colon cancer—RBM26-AS1 micropeptide shown to promote tumor cell growth and colony formation)Potential indirect roles in other diseases where non-coding RNAs regulate gene expression, though distinct evidence so far is limited to cancer
05

Safety considerations

None reported, as RBM26-AS1 is not a pharmacological target; however, targeting lncRNAs in therapy raises potential risks of off-target gene regulation
06

Biomarkers

Elevated expression of RBM26-AS1 (and its micropeptide) in colon cancer may serve as a prognostic biomarker, but this requires further validation

Beyond the preview

Go deeper on RBM26 antisense RNA 1 (RBM26-AS1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on RBM26 antisense RNA 1 (RBM26-AS1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call